BibTex RIS Cite

-

Year 2011, Volume: 24 Issue: 1, 31 - 37, 21.04.2015

Abstract

-

References

  • Cottler-Fox M, Lapidot T, Petit I, et al. Stem cell
  • mobilization. Hematology 2003;419-437.
  • Lee JL, Kim SB, Lee GW, et al. Clinical
  • usefulness of the hematopoietic progenitor cell
  • counts in predicting the optimal timing of
  • peripheral blood stem cell harvest. J Korean
  • Med Sci 2003; 18: 27-35. doi: 10.1111/j.0041-
  • 2004.04166.x
  • Rainer Moog. Management strategies for poor
  • peripheral blood stem cell mobilization. Transfus
  • Apher Sci. 2008; 38: 229–236. doi:
  • 1016/j.transci.2008.04.002
  • Mendrone A Jr, Arrais CA, Saboya R, Chamone
  • DA, Frederico Luiz Dulley FL. Factors affecting
  • hematopoietic progenitor cell mobilization: An
  • analysis of 307 patients. Transfus Apher Sci.
  • ; 39: 187–192. doi:
  • 1016/j.transci.2008.09.012
  • Arslan O, Moog R. Mobilization of peripheral
  • blood stem cells. Transfusion and Apheresis
  • Science 2007; 37: 179–185. doi:
  • 1016/j.transci.2007.08.002
  • Weaver CH, Schwartzberg LS, Birch R, et al.
  • Collection of peripheral blood progenitor cells
  • after the administration of cyclophosphamide,
  • etoposide, and granulocyte-colony-stimulating
  • factor: an analysis of 497 patients. Transfusion
  • ;37:896–903. doi:10.1046/j.1537-
  • 1997.37997454014.x
  • Haas R, Möhle R, Frühauf S, et al. Patient
  • characteristics associated with successful
  • mobilizing and autografting of peripheral
  • progenitor cells in malignant lymphoma. Blood
  • ;83:3787–3794.
  • Kasparu H, Krieger O, Girschikofsky M, Kolb A,
  • Bettelheim P, Lutz D. Factors influencing the
  • timing of peripheral blood stem cell collection
  • (PBSC). Transfus Apheresis Sci 1996;17:595–
  • -
  • Ikeda K, Kozuka T, Harada M. Factors for PBPC
  • collection efficiency and collection predictors.
  • Transfus Apher Sci. 2004;31: 245–259. doi:
  • 1016/j.transci.2004.09.008
  • Elliott C, Samson DM, Armitage S, et al. When
  • to harvest peripheral-blood stem cells after
  • mobilization therapy: Prediction of CD34-positive
  • cell yield by preceding day CD34-positive
  • concentration in peripheral blood. J Clin Oncol
  • ; 14:970-973.
  • Gidron A, Singh V, Egan K, Mehta J.
  • Significance of low peripheral blood CD34ş cell
  • numbers prior to leukapheresis: what should the
  • threshold required for apheresis be? Bone
  • Marrow Transplant 2008; 42: 439–442.
  • Mehta J, Oyama Y, Winter J, et al. CD34+ cell
  • collection efficiency does not correlate with the
  • pre-leukapheresis hematocrit. Bone Marrow
  • Transplant 2001; 28: 597–601.
  • Gidron A, Verma A, Doyle M, et al. Can the stem
  • cell mobilization technique influence CD34+ cell
  • collection efficiency of leukapheresis procedures
  • in patients with hematologic malignancies? Bone
  • Marrow Transplant 2005; 35: 243–246. doi:
  • 1038/sj.bmt.1704781
  • Schots R, Van Riet I, Damianos S, et al. The
  • absolute number of circulating CD34+ cells
  • predicts the number of hematopoietic stem cells
  • that can be predicted by apheresis. Bone
  • Marrow Transplant 1996;17:509-15.
  • Schwella N, Beyer J, Schwaner I, et al. Impact of
  • preleukapheresis cell counts on collection
  • results and correlation of progenitor cell dose
  • with engraftment after high-dose chemotherapy
  • in patients with germ-cell cancer. J Clin Oncol
  • ;14:1114-1121.
  • Mohle R, Murea S, Pforsich M, Witt B, Haas R.
  • Estimation of the progenitor cell yield in a
  • leukapheresis product by previous measurement
  • of CD34+ cells in the peripheral blood. Vox Sang
  • ;71:90-196.
  • I. KAYGUSUZ, et al
  • Factors affecting stem cell mobilization
  • Marmara Medical Journal 2011; 24 (1):31-37
  • -
  • Ford C, Chan K, Reilly W, Peterson F. An
  • evaluation of predictive factors for CD34+ cell
  • harvest yields from patients mobilized with
  • chemotherapy and growth factors. Transfusion
  • ;43:622-625. doi: 10.1046/j.1537-
  • 2003.00376.x
  • Moncada V, Bolan C, Yau Y, Leitman S.
  • Analysis of PBPC yields during large volume
  • leukapheresis of subjects with a poor
  • mobilization response to filgrastim. Transfusion
  • ;43:495-501. doi: 10.1046/j.1537-
  • 2003.00361.x
  • Ravagnani F, Siena S, De Reys S, et al.
  • Improved collection of mobilized CD34+
  • hematopoietic progenitor cells by a novel
  • automated leukapheresis system. Transfusion
  • ;39:48–55. doi: 10.1046/j.1537-
  • 1999.39199116894.x
  • Bambi F, Faulkner LB, Azzari C, et al. Pediatric
  • peripheral blood progenitor cell collection:
  • haemonetics MCS 3P versus COBE Spectra
  • versus Fresenius AS104. Transfusion 1998
  • Jan;38(1):70-74.
  • Kishita M. Stability of granulocyte colonystimulating
  • factor (G-CSF) in serum. Clin Rep
  • ;26:221–224.
  • Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of
  • glycosylated and non-glycosylated G-CSFs,
  • alone and in combination with other cytokines,
  • on the growth of human progenitor cells.
  • Anticancer Res 1996;16:1781–1785.
  • Mire-Sluis AR, Das RG, Thorpe R. The
  • international standard for granulocyte colony
  • stimulating factor (G-CSF). Evaluation in an
  • international collaborative study. Participants of
  • the Collaborative Study. J Immunol Methods
  • ;179:117–126.
  • Nissen C, dalle Carbonare Y, Moser Y. In vitro
  • comparison of the biological potency of
  • glycosylated versus non-glycosylated rG-CSF.
  • Drug Invest 1994;7:346–352.
  • Höglund M, Smedmyr B, Bengtsson M, et al.
  • Mobilization of CD34+ cells by glycosylated and
  • nonglycosylated G-CSF in healthy donors –
  • comparative study. Eur J Haematol
  • ;59:177–183. doi: 10.1111/j.1600-
  • 1997.tb00972.x
  • Watts MJ, Addison I, Long SG, et al. Crossover
  • study of the haematological effects and
  • pharmacokinetics of glycosylated and nonglycosylated
  • G-CSF in healthy volunteers. Br J
  • Haematol 1997;98:474–479. doi:
  • 1046/j.1365-2141.1997.2393053
  • Schiødt I, Knudsen LM, Jensen L, et al. Flow
  • cytometry comparison of CD341 subsets in bone
  • marrow and peripheral blood after priming with
  • glycosylated or non-glycosylated rhG-CSF. Bone
  • Marrow Transplant 1998; 21:1167–1169.
  • Tomblyn M, Burns LJ, Blazar B, et al. Difficult
  • stem cell mobilization despite adequate CD34+
  • cell dose predicts shortened progression free
  • and overall survival after autologous HSCT for
  • lymphoma. Bone Marrow Transplant 2007;
  • :111–118. doi: 10.1038/sj.bmt.1705708
  • Dreger P, Kloss M, Petersen B, et al. Autologous
  • progenitor cell transplantation: Prior exposure to
  • stem cell-toxic drugs determines yield and
  • engraftment of peripheral blood progenitor cell
  • but not of bone marrow grafts. Blood 1995;
  • (10): 3970-3978.

Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler

Year 2011, Volume: 24 Issue: 1, 31 - 37, 21.04.2015

Abstract

Amaç: Otolog kök hücre transplantasyonunun başarısı yeterli sayıda kök hücrenin infüzyonuna bağlıdır. Bu nedenle kök hücre mobilizasyonunu etkileyen faktörlerin tanımlanması önem taşımaktadır. Çalışmamızın amacı, otolog kök hücre nakli uygulanan hastalarda kök hücre mobilizasyonunu etkileyen faktörleri belirlemektir.

Hastalar ve Yöntemler: Otolog kök hücre nakli yapılan 143 hasta ve bu hastalara uygulanan 169 kök hücre aferez işlemi retrospektif olarak değerlendirildi.

Bulgular: Kök hücre mobilizasyonu için 89 (%52.7) hastada Filgrastim, 80 (%47.3) hastada Lenograstim kullanıldı. Aferez işleminde 69 (%40.8) hastada Fresenius, 100 (%59.2) hastada Haemonetics cihazı kullanıldı. Tek değişkenli analizlerde tanı (p=0.005), aferez öncesi tedavi sayısı (p:0.0004), tanıdan afereze kadar geçen süre (p:0.02), aferezin 1. günündeki lökosit ve CD34+ hücre sayısı (p:0.0001; p:0.0005), filgrastim kullanımı (p=0.00004) ve fresenius cihazının kullanımı (p:0.007)'nın kök hücre mobilizasyonunu etkileyen faktörler olduğu görüldü. Çok değişkenli analizlerde ise en önemli faktörlerin tanı (p=0.01), filgrastim kullanımı (p=0.001), fresenius cihazının kullanımı (p=0.03) ve aferezin 1. günündeki lökosit sayısı (p=0.006) olduğu saptandı.

Sonuç: Çalışmamızda tanı, filgrastim ile mobilizasyon, fresenius cihazının kullanılması, ve aferezin 1. gününde periferik kandaki WBC sayısının kök hücre mobilizasyonunu etkileyen en önemli değişkenler olduğu saptanmıştır.

 

Anahtar Kelimeler: Kök hücre mobilizasyonu, Hematopoetik periferal kök hücre nakli, Filgrastim, Lenograstim, Aferez

References

  • Cottler-Fox M, Lapidot T, Petit I, et al. Stem cell
  • mobilization. Hematology 2003;419-437.
  • Lee JL, Kim SB, Lee GW, et al. Clinical
  • usefulness of the hematopoietic progenitor cell
  • counts in predicting the optimal timing of
  • peripheral blood stem cell harvest. J Korean
  • Med Sci 2003; 18: 27-35. doi: 10.1111/j.0041-
  • 2004.04166.x
  • Rainer Moog. Management strategies for poor
  • peripheral blood stem cell mobilization. Transfus
  • Apher Sci. 2008; 38: 229–236. doi:
  • 1016/j.transci.2008.04.002
  • Mendrone A Jr, Arrais CA, Saboya R, Chamone
  • DA, Frederico Luiz Dulley FL. Factors affecting
  • hematopoietic progenitor cell mobilization: An
  • analysis of 307 patients. Transfus Apher Sci.
  • ; 39: 187–192. doi:
  • 1016/j.transci.2008.09.012
  • Arslan O, Moog R. Mobilization of peripheral
  • blood stem cells. Transfusion and Apheresis
  • Science 2007; 37: 179–185. doi:
  • 1016/j.transci.2007.08.002
  • Weaver CH, Schwartzberg LS, Birch R, et al.
  • Collection of peripheral blood progenitor cells
  • after the administration of cyclophosphamide,
  • etoposide, and granulocyte-colony-stimulating
  • factor: an analysis of 497 patients. Transfusion
  • ;37:896–903. doi:10.1046/j.1537-
  • 1997.37997454014.x
  • Haas R, Möhle R, Frühauf S, et al. Patient
  • characteristics associated with successful
  • mobilizing and autografting of peripheral
  • progenitor cells in malignant lymphoma. Blood
  • ;83:3787–3794.
  • Kasparu H, Krieger O, Girschikofsky M, Kolb A,
  • Bettelheim P, Lutz D. Factors influencing the
  • timing of peripheral blood stem cell collection
  • (PBSC). Transfus Apheresis Sci 1996;17:595–
  • -
  • Ikeda K, Kozuka T, Harada M. Factors for PBPC
  • collection efficiency and collection predictors.
  • Transfus Apher Sci. 2004;31: 245–259. doi:
  • 1016/j.transci.2004.09.008
  • Elliott C, Samson DM, Armitage S, et al. When
  • to harvest peripheral-blood stem cells after
  • mobilization therapy: Prediction of CD34-positive
  • cell yield by preceding day CD34-positive
  • concentration in peripheral blood. J Clin Oncol
  • ; 14:970-973.
  • Gidron A, Singh V, Egan K, Mehta J.
  • Significance of low peripheral blood CD34ş cell
  • numbers prior to leukapheresis: what should the
  • threshold required for apheresis be? Bone
  • Marrow Transplant 2008; 42: 439–442.
  • Mehta J, Oyama Y, Winter J, et al. CD34+ cell
  • collection efficiency does not correlate with the
  • pre-leukapheresis hematocrit. Bone Marrow
  • Transplant 2001; 28: 597–601.
  • Gidron A, Verma A, Doyle M, et al. Can the stem
  • cell mobilization technique influence CD34+ cell
  • collection efficiency of leukapheresis procedures
  • in patients with hematologic malignancies? Bone
  • Marrow Transplant 2005; 35: 243–246. doi:
  • 1038/sj.bmt.1704781
  • Schots R, Van Riet I, Damianos S, et al. The
  • absolute number of circulating CD34+ cells
  • predicts the number of hematopoietic stem cells
  • that can be predicted by apheresis. Bone
  • Marrow Transplant 1996;17:509-15.
  • Schwella N, Beyer J, Schwaner I, et al. Impact of
  • preleukapheresis cell counts on collection
  • results and correlation of progenitor cell dose
  • with engraftment after high-dose chemotherapy
  • in patients with germ-cell cancer. J Clin Oncol
  • ;14:1114-1121.
  • Mohle R, Murea S, Pforsich M, Witt B, Haas R.
  • Estimation of the progenitor cell yield in a
  • leukapheresis product by previous measurement
  • of CD34+ cells in the peripheral blood. Vox Sang
  • ;71:90-196.
  • I. KAYGUSUZ, et al
  • Factors affecting stem cell mobilization
  • Marmara Medical Journal 2011; 24 (1):31-37
  • -
  • Ford C, Chan K, Reilly W, Peterson F. An
  • evaluation of predictive factors for CD34+ cell
  • harvest yields from patients mobilized with
  • chemotherapy and growth factors. Transfusion
  • ;43:622-625. doi: 10.1046/j.1537-
  • 2003.00376.x
  • Moncada V, Bolan C, Yau Y, Leitman S.
  • Analysis of PBPC yields during large volume
  • leukapheresis of subjects with a poor
  • mobilization response to filgrastim. Transfusion
  • ;43:495-501. doi: 10.1046/j.1537-
  • 2003.00361.x
  • Ravagnani F, Siena S, De Reys S, et al.
  • Improved collection of mobilized CD34+
  • hematopoietic progenitor cells by a novel
  • automated leukapheresis system. Transfusion
  • ;39:48–55. doi: 10.1046/j.1537-
  • 1999.39199116894.x
  • Bambi F, Faulkner LB, Azzari C, et al. Pediatric
  • peripheral blood progenitor cell collection:
  • haemonetics MCS 3P versus COBE Spectra
  • versus Fresenius AS104. Transfusion 1998
  • Jan;38(1):70-74.
  • Kishita M. Stability of granulocyte colonystimulating
  • factor (G-CSF) in serum. Clin Rep
  • ;26:221–224.
  • Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of
  • glycosylated and non-glycosylated G-CSFs,
  • alone and in combination with other cytokines,
  • on the growth of human progenitor cells.
  • Anticancer Res 1996;16:1781–1785.
  • Mire-Sluis AR, Das RG, Thorpe R. The
  • international standard for granulocyte colony
  • stimulating factor (G-CSF). Evaluation in an
  • international collaborative study. Participants of
  • the Collaborative Study. J Immunol Methods
  • ;179:117–126.
  • Nissen C, dalle Carbonare Y, Moser Y. In vitro
  • comparison of the biological potency of
  • glycosylated versus non-glycosylated rG-CSF.
  • Drug Invest 1994;7:346–352.
  • Höglund M, Smedmyr B, Bengtsson M, et al.
  • Mobilization of CD34+ cells by glycosylated and
  • nonglycosylated G-CSF in healthy donors –
  • comparative study. Eur J Haematol
  • ;59:177–183. doi: 10.1111/j.1600-
  • 1997.tb00972.x
  • Watts MJ, Addison I, Long SG, et al. Crossover
  • study of the haematological effects and
  • pharmacokinetics of glycosylated and nonglycosylated
  • G-CSF in healthy volunteers. Br J
  • Haematol 1997;98:474–479. doi:
  • 1046/j.1365-2141.1997.2393053
  • Schiødt I, Knudsen LM, Jensen L, et al. Flow
  • cytometry comparison of CD341 subsets in bone
  • marrow and peripheral blood after priming with
  • glycosylated or non-glycosylated rhG-CSF. Bone
  • Marrow Transplant 1998; 21:1167–1169.
  • Tomblyn M, Burns LJ, Blazar B, et al. Difficult
  • stem cell mobilization despite adequate CD34+
  • cell dose predicts shortened progression free
  • and overall survival after autologous HSCT for
  • lymphoma. Bone Marrow Transplant 2007;
  • :111–118. doi: 10.1038/sj.bmt.1705708
  • Dreger P, Kloss M, Petersen B, et al. Autologous
  • progenitor cell transplantation: Prior exposure to
  • stem cell-toxic drugs determines yield and
  • engraftment of peripheral blood progenitor cell
  • but not of bone marrow grafts. Blood 1995;
  • (10): 3970-3978.
There are 154 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

İşık Kaygusuz This is me

Bülent Kantarcıoğlu This is me

Tayfur Toptaş This is me

Güven Yılmaz This is me

Cafer Adıgüzel This is me

Tülin Fıratlı Tuğlular This is me

Emel Demiralp This is me

Mahmut Bayık This is me

Publication Date April 21, 2015
Published in Issue Year 2011 Volume: 24 Issue: 1

Cite

APA Kaygusuz, İ., Kantarcıoğlu, B., Toptaş, T., Yılmaz, G., et al. (2015). Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler. Marmara Medical Journal, 24(1), 31-37.
AMA Kaygusuz İ, Kantarcıoğlu B, Toptaş T, Yılmaz G, Adıgüzel C, Fıratlı Tuğlular T, Demiralp E, Bayık M. Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler. Marmara Med J. August 2015;24(1):31-37.
Chicago Kaygusuz, İşık, Bülent Kantarcıoğlu, Tayfur Toptaş, Güven Yılmaz, Cafer Adıgüzel, Tülin Fıratlı Tuğlular, Emel Demiralp, and Mahmut Bayık. “Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler”. Marmara Medical Journal 24, no. 1 (August 2015): 31-37.
EndNote Kaygusuz İ, Kantarcıoğlu B, Toptaş T, Yılmaz G, Adıgüzel C, Fıratlı Tuğlular T, Demiralp E, Bayık M (August 1, 2015) Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler. Marmara Medical Journal 24 1 31–37.
IEEE İ. Kaygusuz, B. Kantarcıoğlu, T. Toptaş, G. Yılmaz, C. Adıgüzel, T. Fıratlı Tuğlular, E. Demiralp, and M. Bayık, “Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler”, Marmara Med J, vol. 24, no. 1, pp. 31–37, 2015.
ISNAD Kaygusuz, İşık et al. “Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler”. Marmara Medical Journal 24/1 (August 2015), 31-37.
JAMA Kaygusuz İ, Kantarcıoğlu B, Toptaş T, Yılmaz G, Adıgüzel C, Fıratlı Tuğlular T, Demiralp E, Bayık M. Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler. Marmara Med J. 2015;24:31–37.
MLA Kaygusuz, İşık et al. “Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler”. Marmara Medical Journal, vol. 24, no. 1, 2015, pp. 31-37.
Vancouver Kaygusuz İ, Kantarcıoğlu B, Toptaş T, Yılmaz G, Adıgüzel C, Fıratlı Tuğlular T, Demiralp E, Bayık M. Periferik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Kök Hücre Mobilizasyonunu Etkileyen Faktörler. Marmara Med J. 2015;24(1):31-7.